Anchor Investment Management LLC Buys 393 Shares of Edwards Lifesciences Corporation $EW

Anchor Investment Management LLC lifted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 1.0% during the first quarter, Holdings Channel reports. The fund owned 41,740 shares of the medical research company’s stock after acquiring an additional 393 shares during the quarter. Anchor Investment Management LLC’s holdings in Edwards Lifesciences were worth $3,025,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in EW. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $26,000. Vega Investment Solutions acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $27,000. SouthState Corp acquired a new stake in Edwards Lifesciences in the 1st quarter valued at $27,000. Global X Japan Co. Ltd. boosted its stake in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after purchasing an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC boosted its stake in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after purchasing an additional 205 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Activity

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $15,565,087. The trade was a 4.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,014 shares of company stock worth $1,698,844 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Down 0.5%

Shares of EW stock opened at $79.84 on Wednesday. The stock’s fifty day moving average price is $78.86 and its two-hundred day moving average price is $75.29. The company has a market cap of $46.87 billion, a PE ratio of 11.49, a P/E/G ratio of 3.87 and a beta of 1.07. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the business posted $0.70 EPS. Edwards Lifesciences’s revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on EW shares. Deutsche Bank Aktiengesellschaft boosted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, July 25th. Argus upgraded Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Robert W. Baird increased their price target on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, July 25th. Finally, Mizuho upped their price objective on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $86.45.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.